🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT06007495
Recruiting Not applicable

Pilot Physiological Evaluation of an Investigational Mask with Expiratory Washout.

NCT06007495 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2024-05-06
Last updated
2025-03-14

Condition(s) studied

Acute Hypercapnic Respiratory FailureAcute Hypoxemic Respiratory Failure

Investigational drug(s) / intervention(s)

Investigational full-face mask with expiratory washoutConventional full-face mask - single-limbConventional full-face mask - dual-limb

Investigational full-face mask with expiratory washout: With cross-over in randomized order, mask worn for 30 minutes with prescribed single-limb non-invasive ventilation

Conventional full-face mask - single-limb: With cross-over in randomized order, conventional mask such as RT077, worn for 30 minutes with prescribed single-limb non-invasive ventilation

Conventional full-face mask - dual-limb: With cross-over in randomized order, conventional mask such as RT076, worn for 30 minutes with prescribed dual-limb non-invasive ventilation

Study summary

The goal of this pilot randomized cross-over study is to compare the effect of a full-face mask with expiratory washout to a conventional full face mask on non-invasive ventilation (NIV) in patients with acute hypercapnic, and acute hypoxemic, respiratory failure. The main questions it aims to answer are:

* Does a mask with expiratory washout improve minute ventilation in patients using non-invasive ventilation compared with a conventional single-limb NIV mask
* How does a mask with expiratory washout affect respiratory variables compared with a dual-limb NIV mask.

Participants already prescribed NIV will undergo 3 arms of the investigation in a randomized order:

* Single-limb NIV with investigation mask (with expiratory washout)
* Single-limb NIV with conventional mask
* Dual-limb NIV with conventional mask

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * No indication of intubation upon evaluation by physician in the next 2 hours * Fits the investigational mask Specific for hypercapnic patients 1 of the following criteria * Patients hospitalized with acute respiratory failure (ARF) stabilized and tolerating NIV or; * Patient admitted to hospital with ARF with one criteria for NIV among the following: * Acute hypercapnic respiratory failure with hypercapnia and acidosis (Partial pressure of arterial carbon dioxide (PaCO2) \> 45 millimeters of mercury (mmHg) and pH \< 7.38) or * Post-extubation period within 48 hours, in patients with high risk of re-intubation Specific for hypoxemic patients 1 of the following criteria * Hypoxemic respiratory failure without hypercapnia requiring nasal high flow or; * Hypoxemic respiratory failure without hypercapnia requiring NIV or; * Conventional oxygen therapy (COT) \> 6 liters per minute (L/min) with peripheral oxygen saturation (SpO2) \< 92% Exclusion Criteria: * Refusal to participate in the study * Inability to provide informed consent * Infectious isolation * Facial deformity, burns or morphology that prevents adequate mask placement * Claustrophobia * Nausea * Presence of nasogastric tube * Pneumothorax * Confusion or loss of consciousness * Severe upper gastro-intestinal bleeding * Any other condition, which at the investigators discretion, is believed may present a safety risk or impact the feasibility of the study or study results

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Centre hospitalier de l&amp;#39;Université de Montréal (CHUM) Montreal Quebec Recruiting
Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) Québec Quebec Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06007495 on ClinicalTrials.gov ↗ ← All trials in Canada